DGAP-News: Epigenomics AG Announces 2016 First Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: Epigenomics AG Announces 2016 First Quarter Financial Results and Reports on Operational Highlights

DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement Epigenomics AG Announces 2016 First Quarter Financial Results and Reports on Operational Highlights 23.05.2016 / 08:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Press release Epigenomics AG Announces 2016 First Quarter Financial Results and Reports on Operational Highlights Berlin (Germany) and Germantown, MD (U.S.A.), May 23, 2016 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the first quarter 2016 ending March 31. "During the first quarter 2016, our main efforts were focused on the final steps towards FDA approval for our blood-based colorectal cancer screening test Epi proColon(R). After a promising product launch in the U.S. in the current second quarter and initial sales being recorded, we are fully confirming our outlook for 2016", said Dr. Thomas Taapken, CEO/CFO of Epigenomics AG. "Together with our partner Polymedco, we are focusing our efforts on driving adoption by clinical laboratories. In this respect, the recent launch of Epi proColon(R) by LabCorp(R) as the first U.S. laboratory network was a significant milestone." Q1/2016 Financial Results - Product revenue increased by 10% to EUR 186 thousand (Q1 2015: EUR 169 thousand) - Total revenue decreased to EUR 295 thousand (Q1 2015: EUR 367 thousand) mainly due to a shortfall in R&D service income from EUR 157 thousand to EUR 6 thousand. Licensing income increased from EUR 41 thousand to EUR 103 thousand. - Operating costs in Q1 2016 amounted to EUR 5.3 million, up from EUR 3.7 million in Q1 2015. The main driver for this development was a significant increase by EUR 1.6 million in non-cash expenses for share- based compensation, due to the high volatility of our share price between November 2015 and January 2016. Apart from this extraordinary one-off effect, our operating costs in Q1 2016 were at the same level as in Q1 2015. - Net loss for Q1 2016 amounted to EUR 4.3 million (Q1 2015: EUR 3.2 million) translating into a net loss per share for this period of EUR 0.23 (Q1 2015: net loss per share of EUR 0.20). - Cash consumption (cash outflow from operating and investing activities) was EUR 2.4 million in Q1 2016 compared to EUR 2.3 million in Q1 2015. - Liquid assets (including marketable securities) amounted to EUR 8.1 million at the reporting date (Dec 31, 2015: EUR 8.6 million). During the first quarter 2016, four convertible notes were converted by their holders, providing the Company with additional liquidity of EUR 2.1 million. Operational highlights - FDA approval for Epi proColon(R): On April 12, the U.S. Food and Drug Administration (FDA) approved our lead product Epi proColon(R), the first and only blood-based colorectal cancer (CRC) screening test, for commercialization in the United States. This is a great achievement and a truly transformational event for Epigenomics, and it paves the way for us to offer an innovative, convenient and effective CRC screening option to millions of eligible Americans. - Chinese FDA names Septin9 CRC test "innovative medical product": According to the recently published "2015 Medical Device Registration Annual Report" only nine out of 7,530 approved medical devices in China received this label from the local regulators. The CFDA recognizes the domestic initiative and significant clinical value of blood-based Septin9 tests. This official recommendation will significantly support leveraging CRC screening programs in a country where CRC is a rapidly growing medical problem and where about 290 million people would be currently eligible for screening. - License agreement with BioChain: In March 2016, we entered into another strategic license agreement with BioChain on the development and commercialization of Epi proLung(R) in China. In the course of 2016, our partner is expected to initiate a clinical trial to validate our lung cancer detection test with the objective of gaining market approval by the CFDA for this test, too. In view of the high, rapidly growing prevalence of lung cancer among the Chinese population, the commercialization of a novel, blood-based test represents a major business opportunity for both companies. Epigenomics will receive upfront, milestone, and minimum annual payments as well as royalties on future revenues from BioChain and is entitled to commercialize this product exclusively in other markets outside China. - Progress with in-vitro lung-cancer biomarker: In April 2016, we presented data from our clinical research with our proprietary panel of blood-based DNA methylation biomarkers for the detection of lung cancer at the Annual Meeting 2016 of the American Association for Cancer Research (AACR) in New Orleans, LA, U.S.A. The data demonstrates the potential of our assay for the detection of lung cancer and encourages us to conduct additional, potentially larger studies to complete the development of the test. Outlook 2016 fully confirmed - We are forecasting revenue for 2016 to be in the range of EUR 3 to 7 million with the bulk of this in the second half of the year. - We also confirm our expectations for EBIT and EBITDA for 2016 within ranges of EUR -9.0 to -11.0 million (EBIT) and EUR -8.5 to -10.5 million (EBITDA). - Our expectation for cash consumption in 2016 remains unchanged within a range between EUR 8.5 and 9.5 million. Our financial situation has benefited in the meantime from five conversions of convertible notes between January and April 2016. - The positive impact on our share price by the FDA's approval decision has further increased the likelihood that the five convertible notes still outstanding will be converted by their holders before maturity at year-end 2016, so that we now expect that our current liquidity will take us well into 2017. Further Information The full interim statement on the operational highlights and financial results for Q1 2016 can be obtained from Epigenomics' website at: http://www.epigenomics.com/en/news-investors/...l-reports/ 2016.html Conference call for analysts and investors The Company will also host an investor conference call at 2.30 pm CET / 8.30 am EDT, today. The presentation can be followed as a slide show on the website. The dial-in numbers for the conference call are: Dial-in number (within Germany): +49 30 232531366 Dial-in number (within the UK): +44 203 3679216 Dial-in number (within the U.S.A.): + 1 646 7129911 Participants are kindly requested to dial in 10 minutes prior to the start of the call. Both an audio replay of the conference call and a transcript of the conference call will be provided on Epigenomics' website subsequently: http://www.epigenomics.com. Details of both events will be available on Epigenomics' website at http:// www.epigenomics.com/en/news-investors.html - End - Contact Epigenomics AG Peter Vogt Vice President Corporate Communications & Investor Relations Epigenomics AG Geneststraße 5 10829 Berlin Phone +49 (0) 30 24345 386 ir@epigenomics.com http://www.epigenomics.com About Epigenomics Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon(R), is a blood-based screening test for the detection of colorectal cancer. Epi proColon(R) has recently received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, China and selected other countries. The company is based in Germany and the United States. For more information, visit www.epigenomics.com. Epigenomics legal disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward- looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. --------------------------------------------------------------------------- 23.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Epigenomics AG Geneststraße 5 10829 Berlin Germany Phone: +49 30 24345-0 Fax: +49 30 24345-555 E-mail: ir@epigenomics.com Internet: www.epigenomics.com ISIN: DE000A11QW50 WKN: A11QW5 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News Service --------------------------------------------------------------------------- 465603 23.05.2016

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 107

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 60

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 29

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 49

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 68

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 119

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 47

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 61

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 58

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading

Top 5 Most Recently Viewed Articles

Urgent Reminder for WM Technology Shareholders on Lead Plaintiff Deadline

Updated Category News Views 176

Important Information for WM Technology Shareholders The Gross Law Firm is reaching out to shareholders of WM Technology, Inc. (NASDAQ: MAPS). This notice serves as a crucial reminder regarding the upcoming deadline for appointing a lead plaintiff in the class action lawsuit involving the company. Who Should Contact the Gross Law Firm? If you have purchased shares of MAPS...

Continue Reading
Understanding the Class Action Against Methode Electronics, Inc.

Updated Category News Views 68

Key Details of the Class Action Lawsuit In recent events, investors are gearing up as a class action lawsuit looms over Methode Electronics, Inc. (MEI). This action is spawned from various concerns regarding the company's financial disclosures and operational setbacks that have impacted shareholder value significantly. Filing Deadlines for Investors Investors who engaged...

Continue Reading
Janet Yellen Highlights U.S. Economic Strength Amid Election Uncertainty

Updated Category News Views 238

Positive Economic Signals from Janet Yellen As the U.S. presidential election draws near, U.S. Treasury Secretary Janet Yellen has been vocal about her perspectives on the robustness of the nation's economy. Her statements present an optimistic view, highlighting significant developments since the change in administration, particularly under President Biden's leadership....

Continue Reading
Reborn Coffee Sees Impressive Q2 Growth and Expanding Ventures

Updated Category News Views 214

Reborn Coffee's Strong Q2 Sales Growth Reborn Coffee Inc. (NASDAQ: REBN), a prominent name in the specialty coffee market, has reported noteworthy developments emphasizing its growth strategies and market dynamics. With a focus on international expansion and innovative product lines, Reborn Coffee is ambitiously redefining the coffee industry landscape. Impressive Sales...

Continue Reading
Insights into Rent the Runway's Upcoming Q3 2025 Financials

Updated Category News Views 240

Financial Results Announcement by Rent the Runway Rent the Runway, Inc. (NASDAQ: RENT) has exciting news. The company is gearing up to share its financial performance for the third quarter of 2025. This highly anticipated announcement is set for December 12, 2025, before the market opens. Details of the Upcoming Conference Call To discuss its Q3 results, Rent the Runway...

Continue Reading